Skip to content

Healing efficacy, safety and ease of use of a thin Algostéril

Healing efficacy, safety and ease of use of a thin Algostéril in the wounds of maxillofacial surgery

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN38373718
Enrollment
50
Registered
2017-01-19
Start date
2017-01-16
Completion date
Unknown
Last updated
2018-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wound care Skin and Connective Tissue Diseases Wound care

Interventions

All patients have their wounds treated using an Algostéril dressing until wound healing (about one month). Wounds will be redressed every two days maximum. Participants are clinically examined in orde

Sponsors

Les Laboratoires Brothier
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with a wound that needs to be treated with thin Algostéril 2. Those who can be followed until the wound healing 3. Signed informed consent form 4. Aged 18 years and over

Exclusion criteria

Exclusion criteria: 1. Pregnant women 2. Participation in another clinical trial within 30 days prior to inclusion

Design outcomes

Primary

MeasureTime frame
Number of days of treatment to obtain the wound healing is assessed through clinical examination until time of wound healing (approximately 1 month).

Secondary

MeasureTime frame
1. Draining efficiency evaluated by exsudate quantity and local signs of infection at the time of redressing (every 2 days maximum) 2. Ease of use is assessed using a scale of 1 to 4 at the time of redressing (every 2 days maximum) 3. Safety is assessed by recording the type and frequency of adverse events continuously throughout the study

Countries

France

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026